康希諾生物(06185.HK)受政府委託加緊開展新冠病毒疫苗與檢測試劑研發
天津國際生物醫藥聯合研究院公布,天津市科技局1月28日出台「新型冠狀病毒感染應急防治」科技重大專項。研究院孵化畢業企業康希諾生物(06185.HK)、丹娜(天津)生物科技受市專項委託,分別牽頭實施開展「新型冠狀病毒疫苗」和「侵襲性真菌病系列早期檢測試劑盒」研發工作。兩企業同時獲濱海新區應急科技專項支持,加緊研發短期內可投入臨床應用的技術產品,解決新型冠狀病毒感染肺炎相關診療問題。
康希諾生物主要承擔新冠病毒疫苗和臨床前評價研發任務,開展快速滿足應急的多種疫苗技術的評價,研發病毒載體疫苗、mRNA疫苗、重組蛋白疫苗等關鍵技術。丹娜生物基於此前對SARS病毒感染肺炎合併侵襲性真菌感染成為患者死亡的重要原因相關研究,開展對新型冠狀病毒和侵襲性真菌合併感染進行聯合檢測的試劑研發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.